Found 184 articles
Schrödinger, Inc. announced the closing of its initial public offering of 13,664,704 shares of common stock at a public offering price of $17.00 per share, which includes 1,782,352 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds of approximately $232.3 million, before underwriting discounts and commissions and offering expenses payable by the Company.
Schrödinger, Inc. announced the pricing of its initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $202.0 million, before underwriting discounts and commissions and offering expenses payable by the Company.
Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery
Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs.
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary
Nimbus Therapeutics announced the promotion of Chief Medical Officer, Annie C. Chen, M.D., MPH, to President of the company’s Tyk2 subsidiary, Nimbus Lakshmi, Inc.
Disc Medicine is focused on hepcidin biology to restore red blood cell production in hematologic diseases.
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, announced the completion of a $50 million Series A financing.
Schrödinger announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors.
9/20/2019Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology.
Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program
Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers
Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.
Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger
Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.
The M&A moves are expected to increase the oncology pipelines of both companies.
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
Milestone marks advancement of second drug discovery program under the collaboration
Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types
New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs
Schrödinger today announced that Ramy Farid, Ph.D., chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. ET in New York, NY.